Combining accurate, early diagnostic tests for
autoimmune disease, and new antibody treatment options are two themes being
presented by antibody technology experts, ModiQuest Research at HAH 2011 (7-9
November 2011, Cannes, France). ModiQuest Research's technology includes
monoclonal antibody generation and specialist immunological reagents to support
the research and development of new antibody therapies and diagnostics.
President and CEO, Dr Jos Raats will present latest data on new antibodies and
early diagnostics for rheumatoid arthritis, using their hybridoma and phage
display platforms.
Dr Raats said, "The Human Antibodies
and Hybridomas event will be a great opportunity to share knowledge with others
in the field of antibody development. I am honoured to be delivering a paper
entitled
‘Anti-Citrulline Antibody as Novel Therapeutic Drug in early
Rheumatoid Arthritis,' detailing ModiQuest Research's development of
a novel therapy for Rheumatoid Arthritis (RA). Using our antibody
generation technologies, this new drug candidate was developed by focussing on
targets like Deiminated Peptide-Epitopes (DPE), since a number of studies
indicated that these deimination modifications could be responsible for the
initial triggering of autoimmunity and the breaking of tolerance. We use the
same technologies to support our clients in the development of new antibody
therapies and diagnostics."
Modiquest Research are proud to be sponsors of Human
Antibodies & Hybridomas 2011. This year the scientific programme will
include keynote lectures, contributed papers and poster presentations
emphasising all key aspects of human antibody and hybridoma technology,
applications and engineering. The scope of the conference falls broadly into
eight main session categories; infectious diseases, autoimmunity, molecular
biology, emerging technologies, clinical applications, therapeutic
antibodies, cancer and anti-infective antibodies.
ModiQuest Research offers an intelligent approach to
antibody generation, cloning and cell line production. Its offering includes
monoclonal antibody generation, cell line services, plus antibody cloning and
sequencing. Products available in the range include immunological reagents to
enable early research into new antibody therapeutics and diagnostics. These
products contain unique and highly specialised reagents to enable research in
autoimmune disease, infectious diseases including fungal and parasitic diseases
and oncology and are available to purchase online via ModiQuest's website.
For
more information about ModiQuest and to see Dr Raats in action, please click
http://bit.ly/MQR003video or visit
www.modiquestresearch.com
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.